oseltamivir / Generic mfg. - LARVOL DELTA

Association Between Oseltamivir Timing and Clinical Outcomes in Hospitalized Children with Influenza: A Retrospective Cohort Study. (PubMed, Pediatric Health Med Ther) - "Early treatment was associated with a significantly lower incidence of pneumonia, otitis media, and acute asthma exacerbation compared to late treatment (P < 0.05 for all). Early initiation of oseltamivir within 48 hours is effective in reducing hospital length of stay and preventing common influenza-related complications."

Clinical data • Journal • Retrospective data • Asthma • Immunology • Infectious Disease • Influenza • Otorhinolaryngology • Pediatrics • Pneumonia • Pulmonary Disease • Respiratory Diseases

Water-compatible acylation reactions with acid chlorides using a flow microreactor. (PubMed, Chem Commun (Camb)) - "This method applies to amines, phenols, thiols, and pharmaceuticals. Acylation of oseltamivir proceeds with a throughput of 2.1 g h-1, demonstrating scalability and practicality."

Journal

A plant gallotannin pentagalloyl d-glucose elicits antiviral activity against influenza A and B viruses through multi-targeting mechanisms. (PubMed, Arch Virol) - "Of note, PGG was shown to have potent inhibitory activity against both influenza A and B viral neuraminidases (NA) than oseltamivir phosphate (OP), the prodrug of the most widely used antiviral drug against the viral infections...Comparative analyses of antiviral activity between PGG and OP demonstrated that PGG has multi-target antiviral mechanisms involving virucidal activity, HA inhibition, NA inhibition, and replication inhibition in cells. Our data demonstrate the promising potential of PGG to be an attractive antiviral agent against influenza A and B virus infections."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Discovery and Optimization of Benzenesulfonamides as Potent Influenza A Virus Hemagglutinin Inhibitors. (PubMed, J Med Chem) - "The lead compound (S)-63 demonstrated over 10-fold enhanced potency against an oseltamivir-resistant strain of H1N1 (EC50 = 0.23 μM) versus the parent F0045(S) (EC50 = 2.94 μM). In a lethal influenza mouse model, preferred compounds (S)-63 and 27 achieved 20-30% survival, while F0045(S) provided 0% protection, establishing clear in vivo efficacy improvement. This study establishes a novel sulfonyl-containing chemotype for HA inhibition, providing a distinct scaffold for the development of next-generation influenza therapeutics."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Impact of a structured influenza seminar on pediatric residents' knowledge and attitudes: a pre-post single-group study. (PubMed, Turk J Pediatr) - "Knowledge regarding transmission routes and oseltamivir-related adverse effects improved significantly (p < 0.05), while chemoprophylaxis-related items showed mixed changes in correct response rates...A single, structured educational seminar was associated with improvements in several domains of influenza-related knowledge among pediatric residents. The observed declines in selected chemoprophylaxis items indicate that some topics may require repeated or reinforced educational approaches."

Journal • CNS Disorders • Epilepsy • Infectious Disease • Influenza • Pain • Pediatrics • Respiratory Diseases

Oseltamivir aziridines are potent influenza neuraminidase inhibitors and imaging agents. (PubMed, Proc Natl Acad Sci U S A) - "The inhibitors demonstrate formidable activity against diverse viral neuraminidases, including H5N1, and further enable imaging and quantification of active NA. With their dual therapeutic and diagnostic potential, these first-in-class inhibitors indeed benefit from transition state mimicry and covalency, and thus offer a powerful platform for antiviral development and neuraminidase imaging, addressing urgent global health needs in influenza treatment and prevention."

Journal • Infectious Disease • Influenza • Respiratory Diseases

Suraxavir Marboxil And Oseltamivir for Influenza Prophylaxis Under a Hospital-based Setting (clinicaltrials.gov) - P3 | N=384 | Recruiting | Sponsor: Capital Medical University | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Influenza • Respiratory Diseases

Evaluating baloxavir and oseltamivir for influenza: a real-world comparison of hospitalisation risk and safety (ESCMID Global 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Infectious Disease • Influenza • Respiratory Diseases

Potent anti-influenza activity of Adiantum capillus-veneris extract against H1N1: assesing its synergy with oseltamivir (ESCMID Global 2026) - No abstract available

Infectious Disease • Influenza • Respiratory Diseases

Antiviral efficacy of baloxavir marboxil, favipiravir, and oseltamivir in adults with acute non-severe influenza virus infection: an open-label, phase II, randomised, controlled, adaptive platform trial (ESCMID Global 2026) - No abstract available

Clinical • P2 data • Infectious Disease • Influenza • Respiratory Diseases

TREATment of Lower Respiratory Tract Infection in Selected Hospitals in Southern Sri Lanka (TREAT-SL): study protocol for a stepped-wedge, cluster-randomized clinical trial. (PubMed, Trials) - P=N/A | "Results of this clinical trial will provide information on the impact of the RespiQuestAB on antibacterial use and clinical outcomes among patients with LRTI in an LMIC setting."

Clinical • Journal • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Afebrile Presentation in COPD Patients with Influenza A: A Risk Factor for Prolonged Viral Shedding. (PubMed, Int J Chron Obstruct Pulmon Dis) - "To investigate the risk factors for prolonged viral shedding in influenza A patients treated with oseltamivir and analyze fever patterns in chronic obstructive pulmonary disease (COPD) patients...Early antiviral therapy and targeted management for high-risk groups (especially COPD patients) are valuable. Afebrile presentations in COPD patients highlight the importance of routine influenza testing during exacerbations."

Journal • Retrospective data • Chronic Obstructive Pulmonary Disease • CNS Disorders • Immunology • Infectious Disease • Influenza • Pulmonary Disease • Respiratory Diseases • Vascular Neurology

Therapeutic Mechanisms of Early Oseltamivir Administration in the Management of Mild COVID-19 through the Sympathetic Nervous System: A Scoping Review. (PubMed, J Virol Methods) - "This scoping review identifies multiple mechanisms through which oseltamivir may influence COVID-19 pathophysiology. Although evidence remains heterogeneous, findings suggest that oseltamivir may have broader biological effects beyond neuraminidase inhibition. Further clinical studies are needed to clarify its therapeutic role, optimal timing, and potential benefits in unvaccinated or high-risk populations."

Journal • Review • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Performance of GPT-5 for Extraction of Key Clinical Characteristics Around Oseltamivir Use in Hospitalized Pediatric Influenza Patients (PAS 2026) - No abstract available

Clinical • Infectious Disease • Influenza • Pediatrics • Respiratory Diseases

Antiglomerular Basement Membrane Disease Post-URI: A Rarely Reported Entity (SCCM 2026) - "Two weeks earlier she had gone to primary care for cough and sore throat and was prescribed oseltamivir without microbial testing...The patient was treated with nitroglycerin drip, continued HD, plasmapheresis, and pulse-dose corticosteroids. After multidisciplinary discussion, cyclophosphamide was initiated...Most reports were linked to COVID-19 and the COVID-19 vaccine, which may reflect public interest over true increased incidence. While microbial testing did not reveal the culprit pathogen in this patient, this case highlights the uncertainties that remain for this rare illness."

Cough • Glomerulonephritis • Hematological Disorders • Human Immunodeficiency Virus • Immunology • Infectious Disease • Influenza • Lupus Nephritis • Nephrology • Novel Coronavirus Disease • Otorhinolaryngology • Renal Disease • Respiratory Diseases • Respiratory Syncytial Virus Infections • Vasculitis

Concurrent MRSA and MSSA Bacteremia in Critical Care: Diagnostic and Treatment Challenges (SCCM 2026) - "Influenza B was detected on day 2 and treated with oseltamivir. By day 4, recurrent fever and rising leukocytosis led to blood cultures and empiric cefepime and vancomycin...Therapy was adjusted to cefazolin for MSSA and vancomycin for MRSA...Providers should remain alert to the possibility of mixed infections and tailor therapy accordingly. Early recognition, source control, and antimicrobial optimization are essential in optimizing outcomes in such high-risk cases."

Asthma • Cardiovascular • Critical care • Diabetes • Dyslipidemia • Immunology • Infectious Disease • Influenza • Metabolic Disorders • Pneumonia • Respiratory Diseases • Septic Shock • Type 2 Diabetes Mellitus

A VIRAL PLOT TWIST: TURNING THE TIDE IN FULMINANT H1N1 MYOCARDITIS WITH ADVANCED MECHANICAL CIRCULATORY SUPPORT (ACC 2026) - "This case highlights the rarity and severity of fulminant H1N1 myocarditis and underscores the importance of early, multimodal diagnosis and aggressive, guideline-driven management to achieve full cardiac recovery."

Metastases • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Infectious Disease • Inflammation • Influenza • Respiratory Diseases

An unusual presentation of acute kidney injury secondary to Influenza A-induced rhabdomyolysis (UKKW 2026) - "Oseltamivir was initiated but subsequently withdrawn as symptom duration exceeded 7 days...The patient transferred to the intensive care unit for management of a hypertensive emergency, requiring labetalol infusion, amlodipine, doxazosin, clonidine and furosemide for blood pressure control... This case illustrates a rare but serious complication of influenza infection and highlights the importance of screening for influenza virus in the setting of non-traumatic rhabdomyolysis, even in those without typical symptoms and outside of the usual flu season."

Acute Kidney Injury • Cardiovascular • CNS Disorders • Epilepsy • Glomerulonephritis • Hepatology • Immunology • Infectious Disease • Influenza • Liver Failure • Lupus Nephritis • Musculoskeletal Diseases • Myocardial Infarction • Myositis • Nephrology • Renal Disease • Respiratory Diseases

Effectiveness of Xuanfei Jiangzhuo Decoction for Influenza-Induced AECOPD (clinicaltrials.gov) - P=N/A | N=300 | Not yet recruiting | Sponsor: Tianjin Medical University | Trial completion date: Oct 2027 ➔ May 2028 | Initiation date: Mar 2026 ➔ Aug 2026 | Trial primary completion date: Sep 2027 ➔ Mar 2028

Real-world evidence • Trial completion date • Trial initiation date • Trial primary completion date • Chronic Obstructive Pulmonary Disease • Immunology • Infectious Disease • Influenza • Pulmonary Disease • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P3 | N=10000 | Recruiting | Sponsor: UMC Utrecht | Phase classification: P4 ➔ P3 | N=7100 ➔ 10000 | Trial completion date: Dec 2023 ➔ Dec 2025 | Trial primary completion date: Dec 2021 ➔ Dec 2023

Enrollment change • Phase classification • Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P4 | N=6800 | Recruiting | Sponsor: MJM Bonten | N=4000 ➔ 6800 | Trial completion date: Feb 2019 ➔ Jun 2022 | Trial primary completion date: Feb 2019 ➔ Dec 2021 | Initiation date: Dec 2015 ➔ Apr 2016

Enrollment change • Trial completion date • Trial initiation date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P4 | N=7100 | Recruiting | Sponsor: MJM Bonten | Trial completion date: Jun 2022 ➔ Dec 2023

Trial completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P4 | N=4000 | Recruiting | Sponsor: UMC Utrecht

New P4 trial • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

REMAP-CAP: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (clinicaltrials.gov) - P3 | N=10000 | Recruiting | Sponsor: UMC Utrecht | Trial completion date: Dec 2025 ➔ Feb 2028 | Trial primary completion date: Dec 2023 ➔ Feb 2026

Trial completion date • Trial primary completion date • Infectious Disease • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases

A Case of Acute Necrotizing Encephalopathy in a Patient With Influenza (AAN 2026) - "Objective: We present a case of rapidly progressive encephalitis originating in the pons and radiating superiorly to involve the hippocampi, accompanied by severe myotonia with profound electrolyte derangement.Background: This is a 57-year old-female with seronegative lupus (on hydroxychloroquine and belimumab) who presented with acute onset dysarthria and gait instability...She tested positive for Influenza A and oseltamivir was started, later changed to peramivir... Her cause of death was determined to be acute necrotizing encephalopathy (ANE), a severe neurologic condition involving fulminant cerebral edema usually triggered by a viral infection. Pathophysiology has not been entirely characterized but is thought to involve a cytokine storm in susceptible hosts. Prompt identification is essential so that high-dose steroids, plasmapheresis, tocilizumab, and/or intravenous immunoglobulin can be initiated."

Clinical • Acute Lung Injury • Cardiovascular • CNS Disorders • Epilepsy • Glomerulonephritis • Immunology • Infectious Disease • Inflammatory Arthritis • Influenza • Lupus • Lupus Nephritis • Nephrology • Respiratory Diseases • IL6